Needham initiated coverage on Mind Medicine Inc. (NASDAQ:MNMD), or MindMed, on Monday. The late-stage clinical biopharmaceutical company is developing novel product candidates to treat brain health disorders.The company’s lead drug candidate, MM120 ODT (lysergide D-tartrate or LSD), is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics that acts as a partial agonist at human serotonin-2A (5-HT2A) receptors.MindMed is developing MM120, the tartrate salt form of lysergide, ...